Chesapeake IRB launches CIRBI in Canada
The integration of Chesapeake IRB and IRB Services is now complete.
After joining forces in April of this year, Chesapeake IRB and IRB Services, both North American leaders in providing central ethical review services, began making plans to integrate submission processes in the United States and Canada utilizing a common, powerful, proven, electronic platform, CIRBI. The integration is now complete. Chesapeake IRB's revolutionary platform, the Center for IRB Intelligence (CIRBI), provides cloud-based access to an entire ethics review project. The fully integrated system unifies all Chesapeake IRB and IRB Services functions under one easy-to-use platform.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
